Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05764161 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
A Phase 3 study of Prurigo Nodularis, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 190
- Enrollment target
- 20
- Study locations
NCT05764161 is a Phase 3 study of Prurigo Nodularis that has completed, run by Incyte Corporation. The registered enrollment target is 190 participants, below the 216-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05764161, a Phase 3 study of Prurigo Nodularis, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 190 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
Conditions Studied
Interventions
- DRUG Ruxolitinib Cream
- DRUG Vehicle Cream
Study Locations (20)
New South Wales
- Premier Specialists Pty Ltd - Kogarah
- Liverpool Hospital - Liverpool
- Holdsworth House Medical Practice - Sydney
- Westmead Hospital - Sydney
California
- Dermatology Research Associates - Los Angeles
- Clinical Science Institute Clinical Research Specialists Inc - Santa Monica
- Cura Clinical Research - Sherman Oaks
Ohio
- Oakview Dermatology - Athens
- Aventiv Research Inc-Dublin - Dublin
- Wright State Physicians, Inc. - Fairborn
Pennsylvania
- University of Pittsburgh Medical Center Upmc Dermatology Clinic Oakland Falk Medical Building - Pittsburgh
- Dermdox Center For Dermatology - Sugarloaf
Alabama
- University of Alabama At Birmingham - Birmingham
Arkansas
- Northwest Arkansas Clinical Trials Center - Arkansas City
Florida
- Ars - Maitland Clinical Research Unit - Orlando
Georgia
- Marietta Dermatology the Skin Cancer Center Marietta - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2023-06-12 |
| Est. Completion | 2025-11-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05764161
The ClinicalTrials.gov registry entry for NCT05764161 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 216-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (12% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib Cream is the first listed.
NCT05764161 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New South Wales, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT05764161 about?
NCT05764161 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)". The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
What is the current status of trial NCT05764161?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2023-06-12. Estimated completion is 2025-11-04.
What conditions does trial NCT05764161 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
What interventions are being tested in trial NCT05764161?
The interventions under investigation include: Ruxolitinib Cream (DRUG), Vehicle Cream (DRUG).
Who is sponsoring clinical trial NCT05764161?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05764161 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
RECRUITING · Phase 3
-
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
ACTIVE NOT RECRUITING · Phase 3
-
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.